早发心房颤动的遗传学评估及其对患者管理的影响
本研究在早发心房颤动(AF)精准医学门诊中评估遗传学检测的结果及治疗影响。264例60岁前诊断AF的患者接受三代家系、心脏影像、动态监测及心肌病/心律失常 panel 基因检测,20%检出致病/可能致病变异,阳性者中52%管理发生改变。
要点
- 早发AF患者遗传学检测阳性率约20%,心肌病、结下传导病和CMR异常预测阳性。
- 基因阳性者52%管理改变,包括7例新置入ICD和16例启动疾病修饰治疗。
- OSA和正常12导联心电图预测遗传学检测阴性。
核心结论
- 早发AF精准医学门诊中20%患者遗传学检测阳性,阳性结果可改变临床管理。
研究设计与样本
- 单中心前瞻性队列,264例60岁前诊断AF的转诊患者,中位年龄47岁,77例(29%)女性,236例(89%)白人。
- 评估包括三代家系、心脏影像、动态监测及心肌病/心律失常 panel 临床基因检测。
主要发现
- 242例(92%)接受基因检测,48例(20%)检出致病或可能致病变异。
- 阳性最强预测因素为心肌病史、结下传导病和CMR T1升高或晚期钆增强(均P < .05)。
- 阴性最强预测因素为阻塞性睡眠呼吸暂停和正常12导联心电图(均P < .04)。
- 基因阳性者中52%临床管理改变,包括7例新ICD置入和16例启动疾病修饰治疗。
临床怎么用
- 对60岁前诊断AF患者可转诊至精准医学门诊,综合家系、影像、监测和基因 panel 评估。
- 基因阳性者应根据结果调整管理,如ICD置入或疾病修饰治疗。
局限性
- 单中心转诊队列,白人占89%,外推性受限。
- 中位随访时间未报告,管理改变的长期获益未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Genetic testing is recommended for select patients with atrial fibrillation (AF). The aims of this study were to define the results of genetic evaluation and its therapeutic impact for patients referred to a dedicated AF precision medicine clinic. METHODS: Patients diagnosed with AF before age 60 were candidates for referral. In addition to standard evaluation with history, physical exam, and electrocardiogram (ECG), genetic evaluation included a three-generation pedigree, cardiac imaging, ambulatory monitoring, and clinical genetic testing with a cardiomyopathy/arrhythmia panel. RESULTS: Overall, 264 participants were referred: the median age was 47 years (Q1, Q3: 38, 55), 77 (29%) were female, and 236 (89%) were White. Median age at AF diagnosis was 39 years (Q1, Q3: 31, 48), and median time from AF diagnosis to evaluation was 3.7 years (Q1, Q3: 0.9, 10). A total of 242 patients (92%) underwent genetic testing, which identified a pathogenic or likely pathogenic variant in 48 (20%). The strongest predictors of positive genetic testing were history of cardiomyopathy, infranodal conduction disease, and elevated T1 or late gadolinium enhancement on cardiac magnetic resonance imaging (all P < .05). The strongest predictors of negative genetic testing were obstructive sleep apnoea and a normal 12-lead ECG (both P < .04). Overall, genetic testing changed clinical management in 52% of patients with positive genetic testing, highlighted by seven new implantable cardioverter-defibrillator placements and initiation of disease-modifying therapy in 16 patients. CONCLUSIONS: Genetic testing was positive in 20% of patients with early-onset AF referred to a dedicated AF precision medicine clinic. Genetic testing results may change clinical management in genotype-positive patients.
引用
- Laws JL, Shabani M, Williams HL, et al. Genetic evaluation of early-onset atrial fibrillation: impact on patient management. Eur Heart J. 2026. PMID: 41166358. doi:10.1093/eurheartj/ehaf829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。